Tag: neuroendocrine tumor treatments
CCF Announces Partnership with Clarified Precision Medicine
The Carcinoid Cancer Foundation (CCF) and Clarified Precision MedicineTM have partnered to offer neuroendocrine tumor (NET) patients the opportunity to receive an expert review of their tumor sequencing results from any commercially available …
READ MORE
Surgical Management of Neuroendocrine Tumors, November 21 Webinar for Patients and Caregivers
You’re invited to participate in a Neuroendocrine Tumor Awareness Month Webinar on November 21 from 7 to 9 pm, Eastern Time, presented by the American Association of Endocrine Surgeons (AAES). Four national experts will discuss the surgical management…
READ MORE
Luncheon with the Experts in New York City — Carcinoid and Neuroendocrine Tumor Patients Are Invited!
The Big Apple Noids support group invites you to join fellow carcinoid and neuroendocrine tumor (NET) patients and three medical experts for lunch on Sunday, May 4 from 12:30 to 3:30 pm in a private dining room at Dorrian’s restaurant in Manhattan…
READ MORE
Treating Neuroendocrine Tumors: New Patent Awarded
Herbert Chen, MD, and Muthusamy Kunnimalaiyaan, Ph.D., of the University of Wisconsin School of Medicine and Public Health in Madison, have received a patent (8,338,482) for a “Modulating Notch1 Signaling Pathway for Treating Neuroendocrine…
READ MORE
FDA Approves Amendment for PRRT Clinical Trial in Texas
BREAKING NEWS: The Food and Drug Administration (FDA) has just approved the RadioIsotope Therapy of America (RITA) Foundation’s amendment to the Investigational New Drug (IND) protocol for intra-hepatic artery administration of Lu-177 Octreotate…
READ MORE
Up-to-the-Minute: News for the Carcinoid and Neuroendocrine Tumor Community
The first device that simultaneously performs PET and MRI scans, a new alpha-emitter-based therapy for NET cancer patients with progressive therapy-resistant tumors, the first–ever randomized virtual clinical trial, over 100 abstracts on carcinoid…
READ MORE
Breaking News: FDA Approves Treatment for pNET Patients
For the first time in nearly three decades, there is a new treatment for pancreatic neuroendocrine tumor patients! The Food and Drug Administration (FDA) today announced its approval of Afinitor© for pNET patients. This is a milestone for the carcinoid/NET…
READ MORE
RadioMedix $2.8 Million Grant from Texas Emerging Technology Fund to Result in New Products that Benefit Carcinoid and Neuroendocrine Cancer Patients
Two innovative products that will enable users to generate and label PET radiotracers on-site at a significantly reduced cost will be developed by RadioMedix, Inc. with a $2.8 million grant from the Texas Emerging Technology Fund. According to Ebrahim…
READ MORE
